Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business

Monday, September 24, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

CAMBRIDGE, Mass., and BASINGSTOKE, England, Sept. 24 Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), theglobal specialty biopharmaceutical company, announced today that SylvieGregoire has been appointed President of its Human Genetic Therapies (HGT)business, effective immediately. Sylvie brings more than 20 years ofmanagement, regulatory affairs, manufacturing and supply chain experience frombiotechnology and pharmaceutical companies including Biogen Idec and Merck &Co. Sylvie replaces David Pendergast, former President of HGT, whoseretirement was announced in March of this year. To ensure a smooth transition,David will continue with Shire through 2007 as an advisor.

In her role as President of Shire Human Genetic Therapies and a member ofShire's Management Committee, Sylvie is responsible for setting the strategicdirection of the HGT business including managing the commercial and pipelinegrowth, directing the R&D and portfolio management processes, overseeing thesupply teams, and also contributing to the execution of the overall strategicdirection of Shire. She will report to Shire Chief Executive Officer, MatthewEmmens, and will be based at the Shire HGT headquarters in Cambridge, MA.

"Sylvie brings an impressive level of knowledge and expertise to ShireHGT, and her leadership will be key to the continued growth of our HGTbusiness as well as to the global organization," said Matthew Emmens, ChiefExecutive Officer of Shire Pharmaceuticals. "We thank David Pendergast for hiscontribution towards the transformation of Shire HGT into a highly successfulbusiness and for creating an engine of future growth for Shire. We wish him anenjoyable and productive retirement."

Shire HGT has several projects in various stages of development, and overthe past 18 months has received approval and launched ELAPRASE(TM) for thetreatment of Hunter syndrome in the U.S., Europe, and Canada, among otherregions. In addition, REPLAGAL(TM), for the treatment of Fabry disease, whichis available in Europe and other regions outside of the US, continues toperform well.

"Shire HGT is well-positioned for sustained growth, with a strongportfolio and pipeline offering a range of potential therapies for patientssuffering from genetic diseases," said Sylvie Gregoire, President of ShireHGT. "Elaprase has been successfully launched globally, Replagal continues toperform well and we have some exciting opportunities in our early pipeline aswell as in our business development prospects. I am very excited about thisnew opportunity and look forward to working with a team of professionalsdedicated to addressing the needs of patients with genetic diseases, andleading our business through its next phase of development."

Sylvie most recently served as Chairwoman of the Board for IDM Pharma.Prior to IDM Pharma, she was President & Chief Executive Officer ofGlycoFi(TM), Inc. (acquired by Merck & Co. in May 2006), a biotechnologycompany developing biologics independently and with partners. Prior to this,Sylvie was EVP of Technical Operations and a member of the management team atBiogen. She also held various senior clinical and regulatory affairs roles atMerck & Co. in the US and abroad. In addition to serving on the Board ofDirectors for IDM Pharma, Thallion Pharmaceuticals and Cubist Pharmaceuticals,she was recently appointed to the Board of Directors of the Greater BostonFood Bank. She is also on the Board of Trustees at the International School ofBoston. Sylvie received her Doctor of Pharmacy degree from the StateUniversity of New York at Buffalo and her pharmacy graduate degree from theUniversite Laval in Quebec City, Canada.

Notes to editors


Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit and h

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store